Doctors respond to ‘data-free’ decision over menopause hormone therapy: ‘It’s not true’
NegativeU.S News

- The US Food and Drug Administration (FDA), led by commissioner Marty Makary, announced the removal of broad black-box warnings from estrogen-related medications for menopause, a decision criticized by physicians for lacking scientific backing and conflating different health issues. Experts expressed concern over the implications of this decision, particularly regarding systemic estrogen therapies, which they argue are more complex than local vaginal products.
- This development raises significant concerns about the FDA's regulatory process and the potential for overstating the benefits of menopause hormone therapy. Physicians fear that such decisions, made without robust data, could lead to misguided health recommendations and impact future drug approvals.
— via World Pulse Now AI Editorial System



